Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in previously-treated MSI-H or dMMR solid tumors
NCT03736889Phase 2Recruiting
- Sponsor
- BeiGene
- Start
- Sep 2018
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in solid tumor, sponsored by BeiGene. Started Sep 2018; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03736889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736889.